Magnesium: a Mineral with Multiple Applications

Total Page:16

File Type:pdf, Size:1020Kb

Magnesium: a Mineral with Multiple Applications SupplementScience Magnesium: A Mineral With Multiple Applications By Gene Bruno, MS, MHS 9 agnesium is an essential • Alcoholism: An increase in magne- as antacids. mineral with multiple sium excretion is common in chronic • Diabetes: Magnesium chloride has functions in the human alcoholism due to poor dietary practices been shown to improve fasting glucose 10,11 body. This includes a and gastrointestinal issues. levels and insulin resistance in diabetes. structural role in bone, • Aging: Research shows that the eld- Magnesium pidolate improved insulin 12 Mcell membranes and chromosomes.1 It is erly tend to have low magnesium intake response and action. needed for more than 300 metabolic and a decrease in intestinal magnesium • Hearing loss: Magnesium aspartate 2 reactions2, including magnesium- absorption. has been shown to reduce hearing loss (in dependent chemical reactions required The Daily Value for magnesium is 400 normal-hearing adults) due to high levels 13 to metabolize carbohydrates and fats in mg, although there are some instances of impulse noises. the production of adenosine triphos- in which higher doses may be indicated. • Kidney stones: Magnesium hydrox- 14 phate (ATP)1, the “energy currency” of ide reduced kidney stones, and eliminat- the body. In addition, magnesium is Deficiency Ramifications ed them in a significant number of cases. 15 required for the synthesis of nucleic Magnesium deficiency leads to patho- Magnesium oxide with vitamin B6 also acids, proteins, carbohydrates, lipids logical changes in the immune system decreased kidney stone formation. and the antioxidant glutathione.1 that are related to the initiating of an • Migraine headache: Trimagnesium 16 17 Magnesium is also required for trans- inflammatory response.5 In addition, dicitrate and magnesium citrate have porting potassium and calcium ions most human cells can only replicate a been shown to reduce the frequency of across cell membranes. The conduction limited number of times before they migraine headache attacks. Magnesium of nerve impulses, muscle contraction, lose the ability to divide, a phenome- oxide was effective in preventing 18 normal heart rhythm1, cell signaling1 and non known as replicative senescence, migraine in children. cell migration (which may be important which seems to play a role in aging. • Mitral valve prolapse: Treatment with 19 in wound healing)1 are also all magne- Recent studies have shown that low magnesium carbonate decreased symp- sium-dependent activities. magnesium accelerates the senescence toms of weakness, chest pain, dyspnea, of human endothelial cells and fibrob- palpitations and anxiety in patients with Magnesium Adequacy lasts. Since several pieces of evidence mitral valve prolapse. Although overt magnesium (Mg) defi- link low magnesium to aging and age- • Osteoporosis: Magnesium hydroxide ciency is not common in healthy individ- related diseases, and the Western diet reduced fractures and increased bone uals who are consuming a balanced is relatively deficient in magnesium, it density in postmenopausal women with 20 diet, the United States Department of has been suggested that correcting osteoporosis. 21 Agriculture, Agricultural Research nutritional intakes of magnesium might • PMS: Magnesium oxide and magne- 22 Service, has reported that 57 percent of contribute to healthier aging and the sium pyrrolidone carboxylic acid have 6 the U.S. population does not meet the prevention of age-related diseases. To been shown to help relieve symptoms of recommended dietary allowance (RDA) correct such magnesium deficiencies, premenstrual syndrome. 23 for levels of Mg.3 Furthermore, there are supplementation with magnesium sup- • Hypertension: Magnesium oxide and 7 24 specific conditions that place individuals plements is effective. magnesium hydroxide reduced blood at a higher risk for Mg deficiency. These pressure in patients with hypertension. include4: Applications for Supplemental • Leg cramps: Magnesium lactate and 25 • Gastrointestinal disorders: Con- Magnesium magnesium citrate significantly reduced ditions involving prolonged diarrhea Research suggests that there are quite a leg cramps in pregnant women. 26 (e.g., Crohn’s disease, celiac disease, few applications for supplemental magne- • Restless legs: Magnesium oxide intestinal inflammation) are associated sium: helped treat restless leg syndrome (peri- with a reduction in magnesium status. • Constipation: Magnesium citrate, sul- odic limb movement during sleep), • Renal magnesium wasting: Long- fate, and hydroxide are used in laxatives. increasing the amount of sleep. 27 term use of diuretics and other medica- Magnesium attracts water into the intes- • Sports nutrition: Magnesium sulfate tions1 can increase urinary excretion of tines, stimulating bowel motility.8 may positively affect sports performance magnesium. Renal damage in diabetes • Antacid: Magnesium carbonate, by decreasing lactic acid levels. mellitus can have a similar effect. hydroxide, oxide and trisilicate are used • Cholesterol levels: Magnesium oxide 38 VITAMIN RETAILER WWW.VITAMINRETAILER.COM I MAY 2013 SupplementScience monohydrate28 significantly improved good, and even better than some other 6 Killilea DW, Maier JA. A connection between total and LDL cholesterol levels while forms tested. magnesium deficiency and aging: new insights from inhibiting platelet aggregation in healthy Now, let’s consider the practical cellular studies. Magnes Res. 2008;21(2):77-82. 7 Galland L. Magnesium and inflammatory bowel subjects. aspects of magnesium source and mag- disease. Magnesium. 1988;7:78-83. • Inflammation: Magnesium oxide nesium absorption by comparing apples 8 Anderson PO, Knoben JE. Handbook of Clinical Drug monohydrate29 reduced C-reactive protein to apples: if you used the 667 mg of Data. 8th ed. Stamford, CT: Appleton & Lange; 1997. levels, a serum marker for inflammation. magnesium citrate and 667 mg of mag- 9 Swain R, et al. South Med J. 1999;92:1040-7. nesium oxide, the total elemental mag- 10 Rodriguez-Moran M, et al. Diabetes Care. nesium you’d receive would be about 2003;26:1147-52. Sources of Magnesium 11 Guerrero-Romero F, et al. Diabetes Metab. Magnesium doesn’t naturally exist by 107 mg from citrate and 400 mg from 2004;30:253-8. itself. Rather it is attached to some type oxide. Even with 6.84 percent greater 12 Paolisso G, Am J Clin Nutr. 1992;55:1161-7. of organic or inorganic acid. Minerals magnesium absorption from citrate, 13 Attias J, Am J Otolaryngol. 1994;15:26-32. attached to acids are called mineral you’d still end up with far more magne- 14 Johansson G, J Urol. 1980;124:770–4. salts. All forms of magnesium used in sium from the oxide source: 15 Rattan V, Urol Res. 1994;22:161-5. dietary supplements provide one or 16 Peikert A, Cephalalgia. 1996;16:257-63. 17 Demirkaya S, J Headache Pain. 2000;1:179-86. 667 mg Net mg more magnesium salts. For example, if % 18 Wang F, Headache. 2003;43:601-10. magnes. salt absorbed you attached citric acid to magnesium, absorbed 19 Lichodziejewska B, et al. Am J Cardiol. 1997; Citrate you would have a magnesium salt 29.64 17.1 mg 79:768-72. called magnesium citrate (which is fre- (16 percent) percent 20 Stendig-Lindberg G, et al. Magnes Res. 1993; 6:155-63. quently touted as being a well-ab- Oxide 22.8 91.2 mg 21 Walker AF, et al. J Womens Health. 1998;7:1157-65. sorbed form of calcium). The issue with (60 percent) percent 22 Facchinetti F, et al. Obstet Gynecol. 1991;78:177-81. different magnesium salts is that they all 23 Sanjuliani AF, Int J Cardiol. 1996;56:177-83. provide different percentages of actual, It may also interest you to know that 24 Widman L, et al. Am J Hypertens. 1993;6:41-5. or elemental, magnesium by weight. a recent study published in the journal, 25 Dahle LO, et al. Am J Obstet Gynecol. 1995; 173: Sticking with the example of magne- Magnesium Research32, found that mag- 175-80. sium citrate, it provides about 16 per- nesium oxide monohydrate had better 26 Hornyak M, et al. Sleep. 1998;21:501-5. cent elemental magnesium.30 absorption than magnesium citrate. In 27 Ç›nar V, Nizaml›o lu M, Mo ulkoc R. The effect of magnesium supplementation on lactate levels of By comparison, magnesium oxide is this case, researchers did a biopsy to sportsmen and sedanter. Acta Physiologica Hungarica. about 60 percent elemental magnesium measure the amount of magnesium that 2006;93(2–3):137–144. —a much higher elemental potency, had been absorbed into the cell. They 28 Shechter M, Saad T, Shechter A, Koren-Morag and clearly a good source of magne- found that more of the magnesium N, Silver BB, Matetzky S. Comparison of magnesium sium. That means to obtain 400 mg of oxide monohydrate got into the cell status using X-ray dispersion analysis following mag- elemental magnesium (the daily value than magnesium citrate. This suggests nesium oxide and magnesium citrate treatment of for this nutrient) you’d have to consume that the reason that other researchers healthy subjects. Magnes Res. 2012; 25(1): 28-39. 29 Shechter M, Saad T, Shechter A, Koren-Morag found higher blood levels of magne- about 2,500 mg of magnesium citrate N, Silver BB, Matetzky S. Comparison of magnesium or 667 mg of magnesium oxide. That’s sium citrate in the blood than magne- status using X-ray dispersion analysis following mag- easily more than triple the amount of sium oxide, is that less of the magne- nesium oxide and magnesium citrate treatment of magnesium citrate tablets you’d have to sium citrate got into the cell. healthy subjects. Magnes Res. 2012; 25(1): 28-39. take compared to magnesium oxide In any case, the bottom line is that 30 Klasco RK (Ed): USP DI® Drug Information for tablets. while some magnesium salts are better the Healthcare Professional. Thomson MICROMEDEX, absorbed than others, what is most Greenwood Village, Colorado 2003. Often when reading the labels of mag- 31 Ranade VV, Somberg JC. Bioavailability and nesium products, the issue of elemental important is to get an adequate ele- Pharmacokinetics of Magnesium After magnesium potency can be confusing or mental amount of the mineral, and to Administration of Magnesium Salts to Humans.
Recommended publications
  • Appendix a Common Abbreviations Used in Medication
    UNIVERSITY OF AMSTERDAM MASTERS THESIS Impact of Medication Grouping on Fall Risk Prediction in Elders: A Retrospective Analysis of MIMIC-III Critical Care Database Student: SRP Mentor: Noman Dormosh Dr. Martijn C. Schut Student No. 11412682 – SRP Tutor: Prof. dr. Ameen Abu-Hanna SRP Address: Amsterdam University Medical Center - Location AMC Department Medical Informatics Meibergdreef 9, 1105 AZ Amsterdam Practice teaching period: November 2018 - June 2019 A thesis submitted in fulfillment of the requirements for the degree of Master of Medical Informatics iii Abstract Background: Falls are the leading cause of injury in elderly patients. Risk factors for falls in- cluding among others history of falls, old age, and female gender. Research studies have also linked certain medications with an increased risk of fall in what is called fall-risk-increasing drugs (FRIDs), such as psychotropics and cardiovascular drugs. However, there is a lack of consistency in the definitions of FRIDs between the studies and many studies did not use any systematic classification for medications. Objective: The aim of this study was to investigate the effect of grouping medications at different levels of granularity of a medication classification system on the performance of fall risk prediction models. Methods: This is a retrospective analysis of the MIMIC-III cohort database. We created seven prediction models including demographic, comorbidity and medication variables. Medica- tions were grouped using the anatomical therapeutic chemical classification system (ATC) starting from the most specific scope of medications and moving up to the more generic groups: one model used individual medications (ATC level 5), four models used medication grouping at levels one, two, three and four of the ATC and one model did not include med- ications.
    [Show full text]
  • Chemicals Used for Chemical Manufacturing Page 1 of 2
    Chemicals used for Chemical Manufacturing Page 1 of 2 Acetic Acid (Glacial, 56%) Glycol Ether PMA Acetone Glycol Ether PNB Acrylic Acid Glycol Ether PNP Activated Carbon Glycol Ether TPM Adipic Acid Glycols Aloe Vera Grease Aluminum Stearate Gum Arabic Aluminum Sulfate Heat Transfer Fluids Amino Acid Heptane Ammonium Acetate Hexane Ammonium Bicarbonate Hydrazine Hydrate Ammonium Bifluoride Hydrochloric Acid (Muriatic) Ammonium Chloride Hydrogen Peroxide Ammonium Citrate Hydroquinone Ammonium Hydroxide Hydroxylamine Sulfate Ammonium Laureth Sulfate Ice Melter Ammonium Lauryl Sulfate Imidazole Ammonium Nitrate Isobutyl Acetate Ammonium Persulfate Isobutyl Alcohol Ammonium Silicofluoride Calcium Stearate Dipropylene Glycol Isopropanolamine Ammonium Sulfate Carboxymethylcellulose Disodium Phosphate Isopropyl Acetate Antifoams Caustic Potash D'Limonene Isopropyl Alcohol Antifreeze Caustic Soda (All Grades) Dodecylbenzene Sulfonic Acid Isopropyl Myristate Antimicrobials Caustic Soda (Beads, Prills) (DDBSA) Isopropyl Palmitate Antimony Oxide Cetyl Alcohol Dowfrost Itaconic Acid Aqua Ammonia Cetyl Palmitate Dowfrost HD Jojoba Oil Ascorbic Acid Chlorine, Granular Dowtherm SR-1 Keratin Barium Carbonate Chloroform Dowtherm 4000 Lactic Acid Barium Chloride Chromic Acid EDTA Lanolin Beeswax Citric Acid (Dry and Liquid) EDTA Plus Lauric Acid Bentonite Coal Epsom Salt Lauryl Alcohol Benzaldehyde Cocamide DEA Ethyl Acetate Lecithin Benzoic Acid Copper Nitrate Ethyl Alcohol (Denatured) Lime Benzyl Alcohol Copper Sulfate Ethylene Glycol Linoleic Acid Bicarbonate
    [Show full text]
  • Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats
    BASIC RESEARCH www.jasn.org Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats Nancy S. Krieger,1 John R. Asplin,2 Ignacio Granja,2 Felix M. Ramos,1 Courtney Flotteron,1 Luojing Chen,1 Tong Tong Wu,3 Marc D. Grynpas,4 and David A. Bushinsky1 1Division of Nephrology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York; 2Litholink Corporation, Laboratory Corporation of America Holdings, Chicago, Illinois; 3Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, New York; and 4Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada ABSTRACT Background The pathophysiology of genetic hypercalciuric stone-forming rats parallels that of human idiopathic hypercalciuria. In this model, all animals form calcium phosphate stones. We previously found that chlorthalidone, but not potassium citrate, decreased stone formation in these rats. Methods To test whether chlorthalidone and potassium citrate combined would reduce calcium phos- phate stone formation more than either medication alone, four groups of rats were fed a fixed amount of a normal calcium and phosphorus diet, supplemented with potassium chloride (as control), potassium citrate, chlorthalidone (with potassium chloride to equalize potassium intake), or potassium citrate plus chlorthalidone. We measured urine every 6 weeks and assessed stone formation and bone quality at 18 weeks. Results Potassium citrate reduced urine calcium compared with controls, chlorthalidone reduced it fur- ther, and potassium citrate plus chlorthalidone reduced it even more. Chlorthalidone increased urine citrate and potassium citrate increased it even more; the combination did not increase it further.
    [Show full text]
  • Second Page Vit Vs 10112011
    DRUG NUTRIENT RESTORATIVE WHOLE- STANDARD PROCESS DEFICIENCY FOOD SUPPLEMENTS NATURAL ALTERNATIVES Cholesterol- Lowering Drugs Baycol, Lescol, Lipitor, Co Q10, Selenium, Zinc Cellular Vitality, Chezyn, Cyruta, Cholaplex, Livton, Mevacor, Zocor Copper Calsol, Folic Acid B12, Livaplex, Garlic 5000mg, Choline, Cataplex E, 21-Day Puriication Program, Colestid, Questran Vit A, Vit B12, Vit D, Vit E, Magnesium Lactate Tuna Omega-3 Oil, Vit K, Folic Acid, Iron, Calcium, Magnesium Lactate, Magnesium, Phosphorus, Zinc Niacinamide B6 Lopid, Tricor Coenzyme Q10, Vit E Diuretics Diuretics: Loop, Thiazide, Vit B1, Vit B6, Magnesium, Min-Tran, Calcium Lactate, A-C Carbamide, Arginex, Potassium Sparing, Misc. Potassium, Zinc, Vit C, Cataplex B, Zinc Renafood, Celery Seed 1:2, Folic Acid, Calcium Drenatrophin PMG Female Hormones Estrogen/HRT: Vit B6, Vit B12, Co Q10, Zinc Cellular Vitality, Chezyn, FemCo, Symplex F, Chaste Evista, Prempro, Folic Acid, Vit C, Magnesium, Folic Acid B12, Mag Lactate Tree, Wild Yam Complex, Premarin, Estratab Cataplex C Black Current Seed Oil, Drenamin, Hypothalmex, Neuroplex, Trace Minerals B-12 Oral Contraceptives: Vitamin B2, Vitamin B6, B6 Niacinamide, Cataplex B/G, N/A Estrastep, Norinyl, Vitamin B12, Folic Acid, Folic Acid B12, Cataplex C, Ortho-Novem, Triphasil Vitamin C, Magnesium, Zinc Magnesium Lactate, Chezyn Laxatives Potassium Organically Bound Minerals Fen-Cho, Colax, Lactic Acid Yeast, Disodium Phosphate, Magnesium Lactate Tranquilizers Major: Haldol, Vesprin Vitamin B2, Coenzyme Q10 Cellular Vitality, Cardioplus
    [Show full text]
  • Purified Sea Salt with Magnesium Carbonate
    Cargill® Food Processing Salts Purified Sea Saltwith Magnesium Carbonate Product Description Physical Information Purified Sea Salt with Magnesium Carbonate This material is a food grade, granular, white crystalline Purified Sea Salt with Magnesium Carbonate sodium chloride product manufactured under stringent PHYSICAL MIN TARGET MAX process control procedures. Cargill Sea Salts are made from Pacific Ocean sea salt, which is harvested from ponds NaCl (%) 99.7 99.96 100 near the San Francisco Bay. Ca & Mg as Ca (%) 0.003 Sulfate as SO4 (%) 0.01 Product Application Water Insolubles (%) 0.025 0.01 Bulk Density (#cu/ft) 69 74 84 This material is intended for table and cooking use, as well as direct application in foods manufactured by the various Bulk Density (g/l) 1105 1185 1345 food processing industries. This material contains Surface Moisture (%) 0.02 Magnesium Carbonate, which is added to improve caking Magnesium Carbonate (%) 0.5 resistance and flowability. PERCENT PARTICLE SIZE MIN TARGET MAX Product Certifications DISTRIBUTION (SCREENS) Sieve - USS 30 Mesh Retained 0 40 50 Cargill® Sea Salts meet USDA, FDA and Food Chemicals Codex for food use. Sieve - USS 40 Mesh Retained 34 Sieve - USS 50 Mesh Retained 16 Cargill® Sea Salts are certified Kosher for Passover (OU-P) SieveCargill - USS 70 Mesh® RetainedSea Salt 8 by the Orthodox Union. Sieve - Retained on Pan 0 1 10 Made with Sun, Wind and Time Allergen Status Harvesting sea salt from San Francisco Bay today is similar to the salt-making process that has been used for centuries. In accordance with the 2004 USA Food Allergen Labeling and Consumer Protection Act (FALCPA), no allergen declarations are required for this product.
    [Show full text]
  • Potassium-Magnesium Citrate Is an Effective Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis
    0022-5347/97/1586-2069$03.00/0 JOURNAL OF UROLOGY Vol. 158,2069-2073, December 1997 Copyright Q 1997 by AMERICANUROLOGICAL ASS~CIATION, INC. Printed in U.S.A. POTASSIUM-MAGNESIUM CITRATE IS AN EFFECTIVE PROPHYLAXIS AGAINST RECURRENT CALCIUM OXALATE NEPHROLITHIASIS BRUCE ETTINGER,* CHARLES Y. C. PAK, JOHN T. CITRON, CARL THOMAS, BEVERLEY ADAMS-HIJET AND ARLINE VANGESSEL From the Diuision of Research, Kaiser Permanente Medical Care Program, Oakland, California, the Department of Mineral Metabolism, Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, Department of Medicine, Kaiser Permanente Medical Center, Walnut Creek, California, Department of Urology, Kaiser Permanente Medical Center, San Francisco, California, and Kaiser Foundation Research Institute, Kaiser Foundation Hospitals, Oakland, California ABSTRACT Purpose: We examined the efficacy of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi. Materials and Methods: We conducted a prospective double-blind study of 64 patients who were randomly assigned to receive placebo or potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years. Results. New calculi formed in 63.6%of subjects receiving placebo and in 12.9%of subjects receiving potassium-magnesiumcitrate. When compared with placebo, the relative risk of treat- ment failure for potassium-magnesium citrate was 0.16 (95%confidence interval 0.05 to 0.46). potassium-magnesium citrate had a statistically significant effect (relative risk 0.10,95%confi- dence interval 0.03 to 0.36) even after adjustment for possible confounders, including age, pretreatment calculous event rate and urinary biochemical abnormalities.
    [Show full text]
  • The Importance of Minerals in the Long Term Health of Humans Philip H
    The Importance of Minerals in the Long Term Health of Humans Philip H. Merrell, PhD Technical Market Manager, Jost Chemical Co. Calcium 20 Ca 40.078 Copper 29 Cu 63.546 Iron Magnesium 26 12 Fe Mg 55.845 24.305 Manganese Zinc 25 30 Mn Zn 55.938 65.380 Table of Contents Introduction, Discussion and General Information ..................................1 Calcium ......................................................................................................3 Copper .......................................................................................................7 Iron ...........................................................................................................10 Magnesium ..............................................................................................13 Manganese ..............................................................................................16 Zinc ..........................................................................................................19 Introduction Daily intakes of several minerals are necessary for the continued basic functioning of the human body. The minerals, Calcium (Ca), Iron (Fe), Copper (Cu), Magnesium (Mg), Manganese (Mn), and Zinc (Zn) are known to be necessary for proper function and growth of the many systems in the human body and thus contribute to the overall health of the individual. There are several other trace minerals requirements. Minimum (and in some cases maximum) daily amounts for each of these minerals have been established by the Institute of
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • Medication Other Information Aches and Pains Constipation Cough/Cold Diarrhea Fever Over the Counter Medications in Pregnancy
    Over the Counter Medications in Pregnancy Women commonly use over the counter medications in pregnancy. This is a list of those medication you may safely use during pregnancy. If you have any questions about these medications and how to use them please contact your Healthcare Provider's office. Unless otherwise stated please take the medication as directed on the manufactures label. Medication Other Information Aches and Pains * Tylenol Extra Strength 500 mg tablet No more than 6 tablets in a 24 hour period * Tylenol 325 mg tablet No more than 8 in a 24 hour period Constipation Stool Softener Increases the amount of water in your stools to make them easier to pass * Colace (docusate sodium) * Surfak (docusate calcium) * Docusate Fiber Laxative Increases the amount of bulk in your stools to make them easier to pass * Metamucil (psyllium) * Fibercon (Calcium polycarbophil 625 mg) Stool Softener/Fiber Laxative Increases the amount of water in your stools to make them easier to pass * Peri-Colace (docusate sodium/sennosides) * Senekot -S (docusate sodium/sennosides) Osmotic Laxative Increases the amount of water in your stools to make them easier to pass * Milk of Magnesia * MiraLax (polyethylene glycol 3350) Cough/Cold Expectorants Help thin mucus and phlegm so they can be coughed up * Robitussin * Guaifenesin Antihistamines Can be used to relieve seasonal allergy and common cold symptoms of nasal congestion, * Chlorpheniramine sneezing and itchy eyes Cough Suppressants Help calm a cough * Dextromethorphan Decongestants Are used to relieve
    [Show full text]
  • Wednesday May 26, 1999
    5±26±99 Vol. 64 No. 101 Wednesday Pages 28333±28712 May 26, 1999 federal register 1 VerDate 06-MAY-99 21:29 May 25, 1999 Jkt 183247 PO 00000 Frm 00001 Fmt 4710 Sfmt 4710 E:\FR\FM\26MYWS.XXX pfrm03 PsN: 26MYWS II Federal Register / Vol. 64, No. 101 / Wednesday, May 26, 1999 The FEDERAL REGISTER is published daily, Monday through SUBSCRIPTIONS AND COPIES Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, PUBLIC Washington, DC 20408, under the Federal Register Act (44 U.S.C. Subscriptions: Ch. 15) and the regulations of the Administrative Committee of Paper or fiche 202±512±1800 the Federal Register (1 CFR Ch. I). The Superintendent of Assistance with public subscriptions 512±1806 Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. General online information 202±512±1530; 1±888±293±6498 Single copies/back copies: The Federal Register provides a uniform system for making available to the public regulations and legal notices issued by Paper or fiche 512±1800 Federal agencies. These include Presidential proclamations and Assistance with public single copies 512±1803 Executive Orders, Federal agency documents having general FEDERAL AGENCIES applicability and legal effect, documents required to be published Subscriptions: by act of Congress, and other Federal agency documents of public Paper or fiche 523±5243 interest. Assistance with Federal agency subscriptions 523±5243 Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing.
    [Show full text]
  • Oral Magnesium Gly Magnesium Glycerophosphate Ceroph
    pat hways Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 Key points from the evidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate in patients who have previously been treated with an intravenous infusion of magnesium. Oral magnesium glycerophosphate does not have UK marketing authorisation for this or any other indication, and therefore it is an unlicensed medicine in the UK. No published clinical trials comparing the efficacy of oral magnesium glycerophosphate with placebo or any form of active treatment for preventing recurrent hypomagnesaemia after treatment with intravenous magnesium were identified. The only videncee found was from 3 case reports describing the use of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia in adults after intravenous treatment. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 17 Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4) Two of the 3 case reports concerned patients who had short bowel syndrome due to surgical resection.
    [Show full text]
  • United States Patent Office Patented Nov
    3,539,306 United States Patent Office Patented Nov. 10, 1970 2 properties of quick activity, durable effect and storage 3,539,306 PROCESS FOR THE PREPARATION Stability, and that, therefore, the same can provide an ex OF HYDROTALCITE cellent, ideal antacid. Teruhiko Kumura and Norio Imataki, Takamatsu-shi, Hydrotalcite is known as a mineral having a chemical Katuyuki Hasui, Kagawa-ken, and Takeo Inoue and 5 Structure of the formula Kimiaki Yasutomi, Nagao-machi, Kagawa-ken, Japan, assignors to Kyowa Chemical Industry Co., Ltd., Tokyo, MgAl(OH) 16CO3 4HO O Al2O3 6MgO CO2: 12H2O Japan, a corporation of Japan No Drawing. Filed July 21, 1967, Ser. No. 654,977 which has been naturally produced in only very limited Claims priority, application Japan, July 25, 1966, areas as Norway and Ural. Also a process for the syn 41/48,349; July 17, 1967, 42/45,658 O thesis of hydrotalcite was disclosed, which comprises add Int. C. COf 5/00, 7/00, A61k 27/06 ing Dry Ice or ammonium carbonate to a mixture of U.S. C. 23-315 4 Claims magnesium oxide and y-alumina or the thermal decom position product from of magnesium nitrate and aluminum nitrate, and thereafter maintaining the system at tempera ABSTRACT OF THE DISCLOSURE, tures below 325 C. and under elevated pressures of total A process for the preparation of hydrotalcite which 2,000-20,000 p.s.i. (Roy et al.: American Journal of comprises mixing an alumium component such as alumi Science 251, 350-353 (1953)). However this process is num Salt With a magnesium component such as magnesium obviously unpractical for industrial scale production of Salt in an aqueous medium in the presence of carbonate hydrotalcite, because the reaction system must be main ion at a pH of at least 8 and thereafter recovering the 20 tained under considerably high pressures.
    [Show full text]